Pharmacyclics clinches $150 million up front from Janssen in blood cancer deal

Pharmacyclics has received $150 million up front under a development and commercialisation deal with Johnson & Johnson unit Janssen Biotech for a first-in-class oral candidate for haematological malignancies currently in Phase II trials.